Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 219 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: vehicle gel Clear all
Completed Phase 2 Interventional Results available

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

NCT05190770
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV
Interventions
Triamcinolone Acetonide, Oleogel-S10
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea

NCT02120924
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid, Vehicle, Finacea
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
30
States / cities
Fremont, California • Santa Monica, California • Brandon, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris

NCT02815332
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BPX-01 1% Minocycline Topical Gel, BPX-01 2% Minocycline Topical Gel, BPX-01 Vehicle Topical Gel
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
9 Years to 40 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Santa Monica, California • Coral Gables, Florida • Lake Mary, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of DER 45-EV Gel to Treat Rosacea

NCT00940992
View directory record Official record
Conditions
Rosacea
Interventions
DER 45 EV, Vehicle
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Miami, Florida • Augusta, Georgia • Fridley, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris

NCT02164084
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Results available

A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions

NCT02052752
View directory record Official record
Conditions
Skin Diseases
Interventions
3% Benzoyl Peroxide, 3% Benzoyl Peroxide Placebo, Neutrogena Rapid Clear®
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of Acne Treatment in Children Ages 9 to 11

NCT00907335
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Retin-A Micro 0.04% facial acne treatment, Vehicle control
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 11 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Encino, California • San Diego, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

NCT06393452
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
PP405 0.05% Topical Gel, Topical Vehicle Gel
Drug
Lead sponsor
Pelage Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
8
States / cities
Encinitas, California • Thousand Oaks, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00888914
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001, Vehicle Comparator
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Francisco, California • New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

NCT03436615
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
SB206 4%, SB206 8%, SB206 12%, Placebo
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
2 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
18
States / cities
Scottsdale, Arizona • Santa Ana, California • Thornton, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne

NCT02404285
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Next Science Acne Gel, Vehicle
Drug
Lead sponsor
Next Science TM
Industry
Eligibility
12 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Jacksonville, Florida • Ponte Vedra, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Multi-Center Study of New Medications to Treat Vaginal Infections

NCT02308033
View directory record Official record
Conditions
Vaginal Infection
Interventions
Metronidazole, Gel vehicle
Drug
Lead sponsor
Curatek Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

NCT03588130
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Carlsbad, California • Fresno, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus, Dermatitis Eczema
Interventions
ASN008 TG, Placebo TG
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Results available

Epiduo Pediatric Acne Study

NCT01138735
View directory record Official record
Conditions
Acne
Interventions
adapalene/benzoyl peroxide, Topical Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years to 11 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Santa Rosa, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

NCT00915551
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 (Ingenol Mebutate) gel, 0.015%, Vehicle Gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Hot Springs, Arizona • Fremont, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 3 Interventional

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

NCT02865005
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan)
Drug · Other
Lead sponsor
Seegpharm S.A.
Industry
Eligibility
12 Years to 40 Years
Enrollment
2,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
35
States / cities
Encino, California • Fullerton, California • La Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy

NCT00695565
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Placebo Gel, Clonidine Topical Gel (ARC-4558)
Drug
Lead sponsor
Arcion Therapeutics Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
16
States / cities
Birmingham, Alabama • Sacramento, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

NCT00375739
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Huntsville, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

NCT02549339
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204 gel, Vehicle gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Carmel, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

NCT03200912
View directory record Official record
Conditions
ACTINIC KERATOSIS
Interventions
Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Oceanside, California • Denver, Colorado • Aventura, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dermal Tolerability of Dapsone Gel in Healthy Volunteers

NCT02117752
View directory record Official record
Conditions
Healthy Volunteers
Interventions
dapsone gel, dapsone gel vehicle, sodium lauryl sulfate, Normal saline
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 4, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

A Study in Subjects With Moderate Atopic Dermatitis

NCT03175354
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Atopic
Interventions
ALX-101 Gel 1.5% and ALX-101 Gel Vehicle, ALX-101 Gel 5% and ALX-101 Gel Vehicle
Drug
Lead sponsor
Ralexar Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Anniston, Alabama • Birmingham, Alabama • Laguna Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 4, 2026, 9:03 AM EDT
Enrolling by invitation Phase 2 Interventional

Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)

NCT07443202
View directory record Official record
Conditions
Ocular Rosacea
Interventions
lotilaner, Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Houston, Texas • Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 4, 2026, 9:03 AM EDT